Across TCGA pan-cancer cohorts, IRAK1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IRAK1 data layer compared with 27 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher IRAK1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated IRAK1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LSCC, PDAC, and UCEC are the cancer types where IRAK1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	0.628	0.916	<.001	28	view →
PDAC	OS	Median	IV	0.491	0.836	.024	6	view →
UCEC	DFS	Tertile	All	0.937	0.779	.029	4	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	3	view →
CCRCC	OS	Quartile	All	0.751	1.000	.025	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: IRAK1 tumor-vs-normal RNA expression · all IRAK1 data types